{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:58:39Z","timestamp":1790708319357,"version":"4.1.0"},"reference-count":228,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Bioeng. Biotechnol."],"DOI":"10.3389\/fbioe.2019.00406","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T04:20:33Z","timestamp":1576556433000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":92,"title":["Nanomedicine Approaches for the Pulmonary Treatment of Cystic Fibrosis"],"prefix":"10.3389","volume":"7","author":[{"given":"Cecilia","family":"Velino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Carella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Adamiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Sanguinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Vitali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Catalucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bugli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Iafisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S0046-8177(82)80056-7","article-title":"The nephropathy of cystic fibrosis: a human model of chronic nephrotoxicity","volume":"13","author":"Abramowsky","year":"1982","journal-title":"Hum. Pathol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1183\/20734735.021014","article-title":"Inhaled therapy in cystic fibrosis: agents, devices and regimens","volume":"11","author":"Agent","year":"2015","journal-title":"Breathe"},{"key":"B3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejpb.2017.08.001","article-title":"Inhalable siRNA-loaded nano-embedded microparticles engineered using microfluidics and spray drying","volume":"120","author":"Agnoletti","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1088\/2057-1976\/aabfac","article-title":"Synthesis and immunological evaluation of a nanovaccine based on PLGA nanoparticles and alginate antigen against infections caused by Pseudomonas aeruginosa","volume":"4","author":"Alikhani","year":"2018","journal-title":"Biomed. Phys. Eng. Express"},{"key":"B5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ijpharm.2007.11.035","article-title":"Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains","volume":"355","author":"Alipour","year":"2008","journal-title":"Int. J. Pharm."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e5724","DOI":"10.1371\/journal.pone.0005724","article-title":"Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis","volume":"4","author":"Alipour","year":"2009","journal-title":"PLoS ONE"},{"key":"B7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejpb.2018.04.006","article-title":"Fabrication of inhaled hybrid silver\/ciprofloxacin nanoparticles with synergetic effect against Pseudomonas aeruginosa","volume":"128","author":"Al-Obaidi","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B8","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S2213-2600(15)00245-3","article-title":"Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Alton","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/ng1093-135","article-title":"Non invasive liposome mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice","volume":"5","author":"Alton","year":"1993","journal-title":"Nat. Genet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"424","DOI":"10.2741\/e102","article-title":"Poloxamine-based nanomaterials for drug delivery","author":"Alvarez-Lorenzo","year":"2010","journal-title":"Front. Biosci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/joim.12314","article-title":"Novel personalized therapies for cystic fibrosis: treating the basic defect in all patients","volume":"277","author":"Amaral","year":"2015","journal-title":"J. Intern. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1126\/science.aau1549","article-title":"Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy","volume":"362","author":"Amoasii","year":"2018","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkg212","article-title":"Development of the quinolones","volume":"51","author":"Andersson","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ijpharm.2010.03.034","article-title":"Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications","volume":"393","author":"Ara\u00fajo","year":"2010","journal-title":"Int. J. Pharm."},{"key":"B15","first-page":"18","article-title":"Nanomedicine for respiratory diseases","volume":"11","author":"Bahadori","year":"2012","journal-title":"Tanaffos"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/S0954-6111(11)70021-X","article-title":"Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics","volume":"105","author":"Ballmann","year":"2011","journal-title":"Respir. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.coi.2014.12.008","article-title":"The roles of CRISPR-Cas systems in adaptive immunity and beyond","volume":"32","author":"Barrangou","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1128\/AAC.40.3.665","article-title":"Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection","volume":"40","author":"Beaulac","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3109\/02652049709051137","article-title":"In vitro kinetics of drug release and pulmonary retention of microencapsulated antibiotic in liposomal formulations in relation to the lipid composition","volume":"14","author":"Beaulac","year":"1997","journal-title":"J. Microencapsul."},{"key":"B20","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12890-016-0339-5","article-title":"Cystic fibrosis lung environment and Pseudomonas aeruginosa infection","volume":"16","author":"Bhagirath","year":"2016","journal-title":"BMC Pulm. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ijpharm.2017.05.046","article-title":"TPP-dendrimer nanocarriers for siRNA delivery to the pulmonary epithelium and their dry powder and metered-dose inhaler formulations","volume":"527","author":"Bielski","year":"2017","journal-title":"Int. J. Pharm."},{"key":"B22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fphar.2019.00020","article-title":"Adapting proteostasis and autophagy for controlling the pathogenesis of cystic fibrosis lung disease","volume":"10","author":"Bodas","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e0184793","DOI":"10.1371\/journal.pone.0184793","article-title":"Dendrimer-based selective autophagy-induction rescues \u03b4F508-CFTR and inhibits Pseudomonas aeruginosa infection in cystic fibrosis","volume":"12","author":"Brockman","year":"2017","journal-title":"PLoS ONE"},{"key":"B24","first-page":"531","article-title":"Small Crispr Rnas guide antiviral defense in prokaryotes","volume":"2","author":"Brouns","year":"1993","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.bbagen.2013.10.018","article-title":"Anti-inflammatory action of lipid nanocarrier-delivered myriocin: therapeutic potential in cystic fibrosis","volume":"1840","author":"Caretti","year":"2014","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"B26","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1021\/mp900138a","article-title":"Partial correction of cystic fibrosis defects with PLGA nanoparticles encapsulating curcumin","volume":"7","author":"Cartiera","year":"2010","journal-title":"Mol. Pharm."},{"key":"B27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nbt.4066","article-title":"A highly specific SpCas9 variant is identified by in vivo screening in yeast","volume":"36","author":"Casini","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s13023-014-0189-2","article-title":"Cysteamine (Lynovex\u00ae), a novel mucoactive antimicrobial and antibiofilm agent for the treatment of cystic fibrosis","volume":"9","author":"Charrier","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.2147\/TCRM.S147164","article-title":"Triplet CFTR modulators: future prospects for treatment of cystic fibrosis","volume":"14","author":"Chaudary","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.2165\/00003495-200363220-00015","article-title":"Inhaled Tobramycin (TOBI\u00ae): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis","volume":"63","author":"Cheer","year":"2003","journal-title":"Drugs"},{"key":"B31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jconrel.2009.10.024","article-title":"An overview of liposome lyophilization and its future potential","volume":"142","author":"Chen","year":"2010","journal-title":"J. Control. Release"},{"key":"B32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: current status, gaps and future directions","volume":"18","author":"Clancy","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"B33","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40265-014-0181-0","article-title":"Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis","volume":"74","author":"Conole","year":"2014","journal-title":"Drugs"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1021\/mp4006358","article-title":"Poly(amidoamine) dendrimer nanocarriers and their aerosol formulations for siRNA delivery to the lung epithelium","volume":"11","author":"Conti","year":"2014","journal-title":"Mol. Pharm."},{"key":"B35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.msec.2018.10.064","article-title":"Biodegradable microparticles designed to efficiently reach and act on cystic fibrosis mucus barrier","volume":"95","author":"Cristallini","year":"2019","journal-title":"Mater. Sci. Eng. C"},{"key":"B36","doi-asserted-by":"publisher","first-page":"E20","DOI":"10.1208\/aapsj070104","article-title":"Carrier-based strategies for targeting protein and peptide drugs to the lungs","volume":"7","author":"Cryan","year":"2005","journal-title":"AAPS J."},{"key":"B37","unstructured":"2017 Patient Registry: Annual Data Report. Cyst. Fibros. Found772018"},{"key":"B38","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s12551-017-0319-x","article-title":"New perspectives in nanotherapeutics for chronic respiratory diseases","volume":"9","author":"da Silva","year":"2017","journal-title":"Biophys. Rev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.addr.2014.05.008","article-title":"Improving the efficacy of inhaled drugs in cystic fibrosis: challenges and emerging drug delivery strategies","volume":"75","author":"d'Angelo","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-3-0348-0977-1_8","article-title":"Anti-inflammatory therapies for cystic fibrosis","volume-title":"Treatment of Cystic Fibrosis and Other Rare Lung Diseases","author":"Dasenbrook","year":"2017"},{"key":"B41","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/B978-0-323-44887-1.00053-5","article-title":"Chapter 53: Molecular therapies for cystic fibrosis","volume-title":"Kendig's Disorders of the Respiratory Tract in Children, 9th Edn","author":"Davies","year":"2019"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1136\/bmj.39391.713229.AD","article-title":"Cystic fibrosis","volume":"335","author":"Davies","year":"2007","journal-title":"Br. Med. J."},{"key":"B43","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"De Boeck","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jcf.2014.09.005","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation","volume":"13","author":"De Boeck","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"B45","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1165\/rcmb.2012-0473OC","article-title":"A decoy oligonucleotide to NF-\u03baB delivered through inhalable particles prevents LPS-induced rat airway inflammation","volume":"49","author":"De Stefano","year":"2013","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/jgm.1546","article-title":"Sustained inhibition of IL-6 and IL-8 expression by decoy ODN to NF-\u03baB delivered through respirable large porous particles in LPS-stimulated cystic fibrosis bronchial cells","volume":"13","author":"De Stefano","year":"2011","journal-title":"J. Gene Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.4161\/15548627.2014.973737","article-title":"Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation","volume":"10","author":"De Stefano","year":"2014","journal-title":"Autophagy"},{"key":"B48","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2217\/nnm.16.26","article-title":"Bioinspired negatively charged calcium phosphate nanocarriers for cardiac delivery of MicroRNAs","volume":"11","author":"Di Mauro","year":"2016","journal-title":"Nanomedicine"},{"key":"B49","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jcf.2005.05.010","article-title":"Anti-inflammatory therapy in cystic fibrosis","volume":"4","author":"Dinwiddie","year":"2005","journal-title":"J. Cyst. Fibros."},{"key":"B50","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jcf.2012.10.004","article-title":"Treatment of lung infection in patients with cystic fibrosis: current and future strategies","volume":"11","author":"D\u00f6ring","year":"2012","journal-title":"J. Cyst. Fibros."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1258096","DOI":"10.1126\/science.1258096","article-title":"The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"B52","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ijpharm.2009.11.033","article-title":"Liposomes as delivery systems for antibiotics","volume":"387","author":"Drulis-Kawa","year":"2010","journal-title":"Int. J. Pharm."},{"key":"B53","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ijpharm.2006.02.017","article-title":"In vitro antimicrobial activity of liposomal meropenem against Pseudomonas aeruginosa strains","volume":"315","author":"Drulis-Kawa","year":"2006","journal-title":"Int. J. Pharm."},{"key":"B54","first-page":"29","article-title":"Pharmacokinetics and Pharmacodynamics of Fluoroquinolones and other Antimicrobial Agents","volume":"45","author":"Drusano","year":"1997","journal-title":"Jap. J. Chemother."},{"key":"B55","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1126\/science.1093941","article-title":"Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects","volume":"304","author":"Egan","year":"2004","journal-title":"Science"},{"key":"B56","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/adma.201201800","article-title":"Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery","volume":"24","author":"Ensign","year":"2012","journal-title":"Adv. Mater."},{"key":"B57","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ejpb.2018.07.025","article-title":"Polyester-based particles to overcome the obstacles of mucus and biofilms in the lung for tobramycin application under static and dynamic fluidic conditions","volume":"131","author":"Ernst","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B58","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.biocel.2014.02.023","article-title":"Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies","volume":"52","author":"Fanen","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/17425247.2019.1575807","article-title":"Novel cystamine-core dendrimer-formulation rescues \u0394F508-CFTR and inhibits Pseudomonas aeruginosa infection by augmenting autophagy","volume":"16","author":"Faraj","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1023\/A:1011925132473","article-title":"Altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low clearance liposomes (MiKasome\u00ae)","volume":"15","author":"Fielding","year":"1998","journal-title":"Pharm. Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1378\/chest.10-0196","article-title":"Chronic macrolide therapy in inflammatory airways diseases","volume":"138","author":"Friedlander","year":"2010","journal-title":"Chest"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s10096-013-1876-y","article-title":"Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review","volume":"32","author":"Gaspar","year":"2013","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B63","doi-asserted-by":"publisher","first-page":"658","DOI":"10.4187\/aarc0537","article-title":"Aerosol antibiotics in cystic fibrosis","volume":"54","author":"Geller","year":"2009","journal-title":"Respir. Care"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1164\/rccm.201008-1293OC","article-title":"Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa","volume":"183","author":"Geller","year":"","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1378\/chest.123.1.28","article-title":"Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system","volume":"123","author":"Geller","year":"2003","journal-title":"Chest"},{"key":"B66","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1089\/jamp.2010.0855","article-title":"Development of an inhaled dry-powder formulation of tobramycin using pulmosphereTM technology","volume":"24","author":"Geller","year":"","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"B67","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/IJN.S13671","article-title":"Stability and antimicrobial effect of amikacin-loaded solid lipid nanoparticles","volume":"6","author":"Ghaffari","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"B68","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ejps.2005.04.009","article-title":"Microencapsulated chitosan nanoparticles for lung protein delivery","volume":"25","author":"Grenha","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"key":"B69","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.addr.2008.09.010","article-title":"Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy","volume":"61","author":"Griesenbach","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B70","doi-asserted-by":"publisher","first-page":"642","DOI":"10.2174\/138161212799315993","article-title":"Progress in gene and cell therapy for cystic fibrosis lung disease","volume":"18","author":"Griesenbach","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"B71","doi-asserted-by":"publisher","first-page":"R52","DOI":"10.1093\/hmg\/ddt372","article-title":"Moving forward: cystic fibrosis gene therapy","volume":"22","author":"Griesenbach","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e0156690","DOI":"10.1371\/journal.pone.0156690","article-title":"Comparative activity of ciprofloxacin, levofloxacin and moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia assessed by minimum inhibitory concentrations and time-kill studies","volume":"11","author":"Grillon","year":"2016","journal-title":"PLoS ONE"},{"key":"B73","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41565-018-0358-x","article-title":"Self-assembled peptide\u2013poloxamine nanoparticles enable in vitro and in vivo genome restoration for cystic fibrosis","volume":"14","author":"Guan","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2174\/157018007784620040","article-title":"In vitro antimicrobial activity of liposomes containing ciprofloxacin,meropenem and gentamicin against gram-negative clinical bacterial strains","volume":"4","author":"Gubernator","year":"2008","journal-title":"Lett. Drug Des. Discov."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1080\/14712598.2017.1347630","article-title":"Adeno-associated virus (AAV) gene therapy for cystic fibrosis: current barriers and recent developments","volume":"17","author":"Guggino","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"B76","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ejpb.2017.04.032","article-title":"Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections","volume":"117","author":"G\u00fcnday T\u00fcreli","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B77","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ijpharm.2006.10.009","article-title":"Dry powder aerosol delivery of large hollow nanoparticulate aggregates as prospective carriers of nanoparticulate drugs: effects of phospholipids","volume":"333","author":"Hadinoto","year":"2007","journal-title":"Int. J. Pharm."},{"key":"B78","doi-asserted-by":"publisher","first-page":"CD003428","DOI":"10.1002\/14651858.CD003428.pub3","article-title":"Inhaled bronchodilators for cystic fibrosis","volume":"2016","author":"Halfhide","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"B79","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/jac\/dkm289","article-title":"Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia","volume":"60","author":"Halwani","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1093\/jac\/dkn422","article-title":"Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa","volume":"62","author":"Halwani","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"B81","doi-asserted-by":"publisher","first-page":"831","DOI":"10.2147\/PPA.S134759","article-title":"Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis of US insurance claims data","volume":"11","author":"Hamed","year":"2017","journal-title":"Patient Prefer. Adherence"},{"key":"B82","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.paed.2019.01.011","article-title":"Modulator therapies for cystic fibrosis","volume":"29","author":"Haq","year":"2019","journal-title":"Paediatr. Child Heal."},{"key":"B83","doi-asserted-by":"publisher","first-page":"16776","DOI":"10.1038\/s41598-018-34960-0","article-title":"Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis","volume":"8","author":"Haque","year":"2018","journal-title":"Sci. Rep."},{"key":"B84","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jcf.2009.04.005","article-title":"Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus","volume":"8","author":"Heijerman","year":"2009","journal-title":"J. Cyst. Fibros."},{"key":"B85","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jcf.2019.02.010","article-title":"The effects of cycled inhaled aztreonam on the cystic fibrosis (CF) lung microbiome","volume":"18","author":"Heirali","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"B86","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.prrv.2007.02.009","article-title":"Mucolytics in cystic fibrosis","volume":"8","author":"Henke","year":"2007","journal-title":"Paediatr. Respir. Rev."},{"key":"B87","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1741-7015-9-32","article-title":"Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis","volume":"9","author":"H\u00f8iby","year":"2011","journal-title":"BMC Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell"},{"key":"B89","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jconrel.2011.07.039","article-title":"A strategy to deliver genes to cystic fibrosis lungs: a battle with environment","volume":"155","author":"Ibrahim","year":"","journal-title":"J. Control. Rel."},{"key":"B90","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1517\/17425247.2011.561310","article-title":"Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease","volume":"8","author":"Ibrahim","year":"","journal-title":"Expert Opin. Drug Deliv."},{"key":"B91","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/jbm.b.30994","article-title":"Comparison of ciprofloxacin hydrochloride-loaded protein, lipid, and chitosan nanoparticles for drug delivery","volume":"86","author":"Jain","year":"2008","journal-title":"J. Biomed. Mater. Res. B Appl. Biomater."},{"key":"B92","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1358\/mf.2001.23.10.677118","article-title":"Pulmonary disposition of budesonide from liposomal dry powder inhaler","volume":"23","author":"Joshi","year":"2001","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ejpb.2008.09.003","article-title":"Lipid nanoparticles for parenteral delivery of actives","volume":"71","author":"Joshi","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B94","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jconrel.2014.03.012","article-title":"Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy","volume":"183","author":"Kaminskas","year":"2014","journal-title":"J. Control. Release"},{"key":"B95","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.powtec.2010.06.003","article-title":"Aqueous re-dispersibility of spray-dried antibiotic-loaded polycaprolactone nanoparticle aggregates for inhaled anti-biofilm therapy","volume":"203","author":"Kho","year":"2010","journal-title":"Powder Technol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.powtec.2009.11.031","article-title":"Aqueous re-dispersibility characterization of spray-dried hollow spherical silica nano-aggregates","volume":"198","author":"Kho","year":"2010","journal-title":"Powder Technol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/CE.S11181","article-title":"Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review","volume":"6","author":"Kirkby","year":"2011","journal-title":"Core Evid."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2018.03.012","article-title":"Biopolymer nanogels improve antibacterial activity and safety profile of a novel lysine-based \u03b1-peptide\/\u03b2-peptoid peptidomimetic","volume":"128","author":"K\u0142odzinska","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1002\/adma.201004048","article-title":"Template-assisted polyelectrolyte encapsulation of nanoparticles into dispersible, hierarchically nanostructured microfibers","volume":"23","author":"Kohler","year":"2011","journal-title":"Adv. Mater."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S0169-409X(02)00146-1","article-title":"Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis","volume":"54","author":"Konstan","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B101","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jconrel.2015.07.024","article-title":"Nanotechnology approaches for inhalation treatment of lung diseases","volume":"219","author":"Kuzmov","year":"2015","journal-title":"J. Control. Release"},{"key":"B102","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/bs.pmch.2018.01.001","article-title":"Recent progress in the discovery and development of small-molecule modulators of CFTR","volume":"57","author":"Kym","year":"2018","journal-title":"Prog. Med. Chem."},{"key":"B103","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ijpharm.2018.09.055","article-title":"Mucus-penetrating phage-displayed peptides for improved transport across a mucus-like model","volume":"553","author":"Leal","year":"2018","journal-title":"Int. J. Pharm."},{"key":"B104","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejpb.2010.12.002","article-title":"Surfactant-free redispersible nanoparticles in fast-dissolving composite microcarriers for dry-powder inhalation","volume":"78","author":"Lebhardt","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B105","doi-asserted-by":"publisher","first-page":"E38","DOI":"10.20944\/preprints201811.0018.v1","article-title":"Applications of CRISPR\/Cas9 for the treatment of duchenne muscular dystrophy","volume":"8","author":"Lim","year":"2018","journal-title":"J. Pers. Med."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1592\/phco.30.12.1279","article-title":"Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing","volume":"30","author":"Lim","year":"2010","journal-title":"Pharmacotherapy"},{"key":"B107","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jcf.2012.03.010","article-title":"A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis","volume":"11","author":"Littlewood","year":"2012","journal-title":"J. Cyst. Fibros."},{"key":"B108","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ajps.2014.12.007","article-title":"Developments of mucus penetrating nanoparticles","volume":"10","author":"Liu","year":"2014","journal-title":"Asian J. Pharm. Sci."},{"key":"B109","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3389\/fphar.2016.00275","article-title":"CFTR modulators: Shedding light on precision medicine for cystic fibrosis","volume":"7","author":"Lopes-Pacheco","year":"2016","journal-title":"Front. Pharmacol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ijpharm.2018.03.058","article-title":"Pseudomonas aeruginosa pyocyanin production reduced by quorum-sensing inhibiting nanocarriers","volume":"544","author":"Lu","year":"2018","journal-title":"Int. J. Pharm."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/cdd.2017.126","article-title":"Strategies for the etiological therapy of cystic fibrosis","volume":"24","author":"Maiuri","year":"2017","journal-title":"Cell Death Differ."},{"key":"B112","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/s41598-017-00662-2","article-title":"Delivery of ENaC siRNA to epithelial cells mediated by a targeted nanocomplex: a therapeutic strategy for cystic fibrosis","volume":"7","author":"Manunta","year":"2017","journal-title":"Sci. Rep."},{"key":"B113","doi-asserted-by":"publisher","first-page":"E1062","DOI":"10.3390\/ijms18051062","article-title":"Inhaled antibiotic therapy in chronic respiratory diseases","volume":"18","author":"Maselli","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-11454-9","article-title":"Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing","volume":"10","author":"Maule","year":"2019","journal-title":"Nat. Commun."},{"key":"B115","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.2147\/IJN.S47551","article-title":"Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology","volume":"8","author":"McKiernan","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"B116","doi-asserted-by":"publisher","first-page":"6952","DOI":"10.1038\/ncomms7952","article-title":"Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium","volume":"6","author":"McNeer","year":"2015","journal-title":"Nat. Commun."},{"key":"B117","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/jac\/dkn059","article-title":"Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections","volume":"61","author":"Meers","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"B118","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.addr.2012.09.021","article-title":"Solid lipid nanoparticles: production, characterization and applications","volume":"64","author":"Mehnert","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B119","doi-asserted-by":"publisher","first-page":"8396","DOI":"10.1039\/C9NJ01591D","article-title":"Dendrimers for pulmonary delivery: current perspectives and future challenges","volume":"43","author":"Mehta","year":"2019","journal-title":"New J. Chem."},{"key":"B120","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.drudis.2010.01.009","article-title":"Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications","volume":"15","author":"Menjoge","year":"2010","journal-title":"Drug Discov. Today"},{"key":"B121","doi-asserted-by":"publisher","first-page":"e79220","DOI":"10.1371\/journal.pone.0079220","article-title":"Transport of nanoparticles and tobramycin-loaded liposomes in Burkholderia cepacia complex biofilms","volume":"8","author":"Messiaen","year":"2013","journal-title":"PLoS ONE"},{"key":"B122","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1080\/17476348.2019.1634547","article-title":"Emerging gene therapies for cystic fibrosis","volume":"13","author":"Miah","year":"2019","journal-title":"Expert Rev. Respir. Med."},{"key":"B123","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1183\/09031936.94.07030442","article-title":"Nasal application of the cationic liposome DC-Chol:DOPE does not alter ion transport, lung function or bacterial growth","volume":"7","author":"Middleton","year":"1994","journal-title":"Eur. Respir. J."},{"key":"B124","doi-asserted-by":"publisher","first-page":"eaan6205","DOI":"10.1126\/scitranslmed.aan6205","article-title":"Inhalation of peptide-loaded nanoparticles improves heart failure","volume":"10","author":"Miragoli","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"B125","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S1569-1993(02)00143-1","article-title":"Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis","volume":"2","author":"Mirakhur","year":"2003","journal-title":"J. Cyst. Fibros"},{"key":"B126","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1517\/17425240802652309","article-title":"Recent advances in liposomal dry powder formulations: Preparation and evaluation","volume":"6","author":"Misra","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"key":"B127","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.pupt.2007.12.001","article-title":"Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway","volume":"21","author":"Moreau-Marquis","year":"2008","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B128","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1093\/jac\/dkv192","article-title":"Pulmonary drug delivery: a review on nanocarriers for antibacterial chemotherapy","volume":"70","author":"Moreno-Sastre","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"B129","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1089\/hum.2007.022","article-title":"Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial","volume":"18","author":"Moss","year":"2007","journal-title":"Hum. Gene Ther."},{"key":"B130","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1378\/chest.125.2.509","article-title":"Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial","volume":"125","author":"Moss","year":"2004","journal-title":"Chest"},{"key":"B131","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/jac\/dkh518","article-title":"Liposome-mediated gentamicin delivery: development and activity against resistant strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients","volume":"55","author":"Mugabe","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"B132","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1128\/AAC.01547-05","article-title":"Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of Pseudomonas aeruginosa","volume":"50","author":"Mugabe","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"B133","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art","volume":"50","author":"M\u00fcller","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B134","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1016\/S0169-409X(02)00118-7","article-title":"Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations","volume":"54","author":"M\u00fcller","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B135","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijpharm.2006.02.045","article-title":"Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN\u00ae) versus drug nanocrystals","volume":"317","author":"M\u00fcller","year":"2006","journal-title":"Int. J. Pharm."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.nano.2015.01.007","article-title":"Inhalable nanoparticulate powders for respiratory delivery","volume":"11","author":"Muralidharan","year":"2015","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1164\/rccm.201601-0154OC","article-title":"Discovery of clinically approved agents that promote suppression of cystic fibrosis transmembrane conductance regulator nonsense mutations","volume":"194","author":"Mutyam","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B138","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1378\/chest.124.1.360","article-title":"Inhalation of a dry powder tobramycin pulmosphere formulation in healthy volunteers","volume":"124","author":"Newhouse","year":"2003","journal-title":"Chest"},{"key":"B139","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.1128\/AAC.00872-08","article-title":"Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection","volume":"53","author":"Okusanya","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1128\/AAC.38.5.1090","article-title":"Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa","volume":"38","author":"Omri","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0006-2952(02)01346-1","article-title":"Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection","volume":"64","author":"Omri","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/2472630318824334","article-title":"Nanomedicine for Cystic Fibrosis","volume":"24","author":"Ong","year":"2019","journal-title":"SLAS Technol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.pupt.2013.07.010","article-title":"Inhalable DNase I microparticles engineered with biologically active excipients","volume":"26","author":"Osman","year":"2013","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B144","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O'Sullivan","year":"2009","journal-title":"Lancet"},{"key":"B145","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.prrv.2017.03.001","article-title":"Cystic fibrosis in the era of precision medicine","volume":"25","author":"Paranjape","year":"2018","journal-title":"Paediatr. Respir. Rev."},{"key":"B146","doi-asserted-by":"publisher","first-page":"5852","DOI":"10.3390\/ijms15045852","article-title":"Nanoparticle-mediated pulmonary drug delivery: a review","volume":"15","author":"Paranjpe","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"B147","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ijpharm.2008.10.003","article-title":"Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products","volume":"366","author":"Pardeike","year":"2009","journal-title":"Int. J. Pharm."},{"key":"B148","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.prrv.2016.10.005","article-title":"Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease","volume":"22","author":"Perry","year":"2017","journal-title":"Paediatr. Respir. Rev."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1345\/aph.1R076","article-title":"Los medicamentos modificadores de la regulaci\u00f3n de la conducci\u00f3n de la fibrosis qu\u00edstica a trav\u00e9s de la membrana (CFTR): el futuro del tratamiento de la fibrosis qu\u00edstica","volume":"46","author":"Pettit","year":"2012","journal-title":"Ann. Pharmacother."},{"key":"B150","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ejpb.2007.05.005","article-title":"Pharmacoscintigraphic and pharmacokinetic evaluation of tobramycin DPI formulations in cystic fibrosis patients","volume":"68","author":"Pilcer","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B151","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s11095-006-9789-4","article-title":"Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation","volume":"23","author":"Pilcer","year":"2006","journal-title":"Pharm. Res."},{"key":"B152","first-page":"506","article-title":"Pellets as carriers of solid lipid nanoparticles (SLN) for oral administration of drugs","volume":"54","author":"Pinto","year":"1999","journal-title":"Pharmazie"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.3389\/fmicb.2018.01349","article-title":"Electrochemically synthesized silver nanoparticles are active against planktonic and biofilm cells of Pseudomonas aeruginosa and other cystic fibrosis-associated bacterial pathogens","volume":"9","author":"Pompilio","year":"2018","journal-title":"Front. Microbiol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"170124","DOI":"10.1183\/16000617.0124-2017","article-title":"A European regulatory perspective on cystic fibrosis: current treatments, trends in drug development and translational challenges for CFTR modulators","volume":"27","author":"Ponzano","year":"2018","journal-title":"Eur. Respir. Rev."},{"key":"B155","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1021\/acsami.7b14992","article-title":"Mucus and cell-penetrating nanoparticles embedded in nano-into-micro formulations for pulmonary delivery of ivacaftor in patients with cystic fibrosis","volume":"10","author":"Porsio","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"B156","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/sj.gt.3300390","article-title":"Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis","volume":"4","author":"Porteous","year":"1997","journal-title":"Gene Ther."},{"key":"B157","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3389\/fphar.2019.00121","article-title":"Emerging therapeutic approaches for cystic fibrosis. From gene editing to personalized medicine","volume":"10","author":"Pranke","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12967-017-1193-9","article-title":"Cystic fibrosis: current therapeutic targets and future approaches","volume":"15","author":"Rafeeq","year":"2017","journal-title":"J. Transl. Med."},{"key":"B159","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1056\/NEJM199607183350307","article-title":"Management of pulmonary disease in patients with cystic fibrosis","volume":"335","author":"Ramsey","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B161","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system HHS Public Access","volume":"8","author":"Ran","year":"2013","journal-title":"Nat Protoc"},{"key":"B162","doi-asserted-by":"publisher","first-page":"595","DOI":"10.4187\/aarc0427","article-title":"Cystic fibrosis: pathogenesis and future treatment strategies","volume":"54","author":"Ratjen","year":"2009","journal-title":"Respir. Care"},{"key":"B163","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1038\/s41467-018-04894-2","article-title":"In utero nanoparticle delivery for site-specific genome editing","volume":"9","author":"Ricciardi","year":"2018","journal-title":"Nat. Commun."},{"key":"B164","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.biomaterials.2014.12.051","article-title":"Evaluation of tetrafunctional block copolymers as synthetic vectors for lung gene transfer","volume":"45","author":"Richard-Fiardo","year":"2015","journal-title":"Biomaterials"},{"key":"B165","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/j.ymthe.2018.05.014","article-title":"Lipid nanoparticle-delivered chemically modified mRNA restores chloride secretion in cystic fibrosis","volume":"26","author":"Robinson","year":"2018","journal-title":"Mol. Ther."},{"key":"B166","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1039\/b901054h","article-title":"Dendrimers and nanomedicine: multivalency in action","volume":"33","author":"Rolland","year":"2009","journal-title":"New J. Chem."},{"key":"B167","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1056\/NEJMra043184","article-title":"Mechanisms of disease cystic fibrosis","volume":"352","author":"Rowe","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B168","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1159\/000445116","article-title":"Liposome delivery systems for inhalation: a critical review highlighting formulation issues and anticancer applications","volume":"25","author":"Rudokas","year":"2016","journal-title":"Med. Princip. Pract."},{"key":"B169","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.colsurfb.2015.12.017","article-title":"Disintegration of nano-embedded microparticles after deposition on mucus: a mechanistic study","volume":"139","author":"Ruge","year":"2016","journal-title":"Colloids Surfaces B Biointerfaces"},{"key":"B170","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ijantimicag.2005.10.021","article-title":"Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: a time-kill study","volume":"27","author":"Rukholm","year":"2006","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B171","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/S0304-4165(99)00078-1","article-title":"Evaluation of the pulmonary and systemic immunogenicity of Fluidosomes, a fluid liposomal-tobramycin formulation for the treatment of chronic infections in lungs","volume":"1428","author":"Sachetelli","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"B172","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S0005-2736(99)00217-5","article-title":"Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells","volume":"1463","author":"Sachetelli","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"B173","doi-asserted-by":"publisher","first-page":"914","DOI":"10.3109\/1061186X.2013.829078","article-title":"Nanotechnology approaches for inhalation treatment of fibrosis","volume":"21","author":"Savla","year":"2013","journal-title":"J. Drug Target"},{"key":"B174","first-page":"369","article-title":"In vivo synergistic interaction of liposome-coencapsulated gentamicin and ceftazidime","volume":"298","author":"Schiffelers","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B175","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1136\/thoraxjnl-2012-202059","article-title":"Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study","volume":"68","author":"Schuster","year":"2013","journal-title":"Thorax"},{"key":"B176","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.stem.2013.11.002","article-title":"Functional repair of CFTR by CRISPR\/Cas9 in intestinal stem cell organoids of cystic fibrosis patients","volume":"13","author":"Schwank","year":"2013","journal-title":"Cell Stem Cell"},{"key":"B177","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s41030-015-0007-6","article-title":"Colobreathe\u00ae for the treatment of cystic fibrosis-associated pulmonary infections","volume":"1","author":"Schwarz","year":"2015","journal-title":"Pulm. Ther."},{"key":"B178","doi-asserted-by":"publisher","first-page":"371","DOI":"10.23736\/S0026-4946.19.05509-9","article-title":"Inhaled medications in cystic fibrosis beyond antibiotics","volume":"71","author":"Sepe","year":"2019","journal-title":"Minerva Pediatr."},{"key":"B179","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.ijpharm.2003.09.041","article-title":"Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung","volume":"269","author":"Sham","year":"2004","journal-title":"Int. J. Pharm."},{"key":"B180","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12325-015-0179-3","article-title":"Use of inhaled tobramycin in cystic fibrosis","volume":"32","author":"Shteinberg","year":"2015","journal-title":"Adv. Ther."},{"key":"B181","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0168-3659(96)01579-9","article-title":"Peptide delivery via the pulmonary route: a valid approach to local and systemic delivery","volume":"46","author":"Smith","year":"1997","journal-title":"J. Control. Release"},{"key":"B182","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/j.jcf.2014.03.010","article-title":"European cystic fibrosis society standards of care: best practice guidelines","volume":"13","author":"Smyth","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"B183","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4155\/tde.14.94","article-title":"Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis","volume":"6","author":"Somayaji","year":"2015","journal-title":"Ther. Deliv."},{"key":"B184","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.pupt.2018.04.007","article-title":"Intravenous fosfomycin for pulmonary exacerbation of cystic fibrosis: real life experience of a large adult CF centre","volume":"50","author":"Spoletini","year":"2018","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B185","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s40261-013-0082-0","article-title":"Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase i study","volume":"33","author":"Stass","year":"","journal-title":"Clin. Drug Investig."},{"key":"B186","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.clinthera.2013.08.003","article-title":"Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study","volume":"35","author":"Stass","year":"","journal-title":"Clin. Ther."},{"key":"B187","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/sj.gt.3301994","article-title":"Poly (D, L-lactide-co-glycolide)\/DNA microspheres to facilitate prolonged transgene expression in airway epithelium in vitro, ex vivo and in vivo","volume":"10","author":"Stern","year":"2003","journal-title":"Gene Ther."},{"key":"B188","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1146\/annurev.bi.46.070177.003451","article-title":"Polymyxin and related peptide antibiotics","volume":"46","author":"Storm","year":"1977","journal-title":"Annu. Rev. Biochem."},{"key":"B189","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jconrel.2014.01.007","article-title":"Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier","volume":"178","author":"Suk","year":"2014","journal-title":"J. Control. Release"},{"key":"B190","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2217\/nnm.10.123","article-title":"Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine","volume":"6","author":"Suk","year":"2011","journal-title":"Nanomedicine"},{"key":"B191","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1016\/j.biomaterials.2008.12.076","article-title":"The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles","volume":"30","author":"Suk","year":"2009","journal-title":"Biomaterials"},{"key":"B192","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.tibtech.2007.09.005","article-title":"Nanoparticles for drug delivery to the lungs","volume":"25","author":"Sung","year":"2007","journal-title":"Trends Biotechnol."},{"key":"B193","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1136\/thoraxjnl-2017-210670","article-title":"Effective silencing of ENaC by siRNA delivered with epithelial-targeted nanocomplexes in human cystic fibrosis cells and in mouse lung","volume":"73","author":"Tagalakis","year":"2018","journal-title":"Thorax"},{"key":"B194","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1007\/s11051-014-2342-1","article-title":"Bioapplications of poly(amidoamine) (PAMAM) dendrimers in nanomedicine","volume":"16","author":"Taghavi Pourianazar","year":"2014","journal-title":"J. Nanoparticle Res."},{"key":"B195","doi-asserted-by":"publisher","first-page":"00082","DOI":"10.1183\/23120541.00082-2019","article-title":"Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles","volume":"5","author":"Taylor-Cousar","year":"2019","journal-title":"ERJ Open Res."},{"key":"B196","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1211\/CP.2016.20201932","article-title":"Conventional therapies and emergent precision medicines for cystic fibrosis: challenges and opportunities","volume":"8","author":"Thompson","year":"2016","journal-title":"Clin. Pharm."},{"key":"B197","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1295\/polymj.17.117","article-title":"A new class of polymers: starburst-dendritic macromolecules","volume":"17","author":"Tomalia","year":"1985","journal-title":"Polym. J."},{"key":"B198","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.colsurfb.2007.07.016","article-title":"Preparation and properties of inhalable nanocomposite particles: effects of the temperature at a spray-dryer inlet upon the properties of particles","volume":"61","author":"Tomoda","year":"2008","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"B199","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/cdd.2016.22","article-title":"A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR","volume":"23","author":"Tosco","year":"2016","journal-title":"Cell Death Differ."},{"key":"B200","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/21678707.2018.1483231","article-title":"Repurposing therapies for the personalised treatment of cystic fibrosis","volume":"6","author":"Tosco","year":"2018","journal-title":"Expert Opin. Orphan Drugs"},{"key":"B201","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1164\/rccm.201105-0924OC","article-title":"Fosfomycin\/tobramycin for inhalation in patients with cystic fibrosis with Pseudomonas airway infection","volume":"185","author":"Trapnell","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B202","doi-asserted-by":"publisher","first-page":"12001","DOI":"10.1073\/pnas.182233999","article-title":"Trojan particles: Large porous carriers of nanoparticles for drug delivery","volume":"99","author":"Tsapis","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B203","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ejpb.2015.03.010","article-title":"Macrophage uptake of cylindrical microparticles investigated with correlative microscopy","volume":"95","author":"Tscheka","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B204","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/01.mcg.0000155140.63510.cd","article-title":"Cystic fibrosis: an overview","volume":"39","author":"Turcios","year":"2005","journal-title":"J. Clin. Gastroenterol."},{"key":"B205","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jconrel.2011.08.010","article-title":"Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers","volume":"157","author":"Ungaro","year":"","journal-title":"J. Control. Release"},{"key":"B206","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1111\/j.2042-7158.2012.01486.x","article-title":"Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises","volume":"64","author":"Ungaro","year":"","journal-title":"J. Pharm. Pharmacol."},{"key":"B207","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1183\/09031936.00212813","article-title":"Medical nanoparticles for next generation drug delivery to the lungs","volume":"44","author":"Van Rijt","year":"2014","journal-title":"Eur. Respir. J."},{"key":"B208","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2165\/11316240-000000000-00000","article-title":"New antimicrobial strategies in cystic fibrosis","volume":"12","author":"Van Westreenen","year":"2010","journal-title":"Pediatr. Drugs"},{"key":"B209","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2147\/MDER.S16360","article-title":"Tobramycin administered by the TOBI\u00ae Podhaler\u00ae for persons with cystic fibrosis: a review","volume":"4","author":"VanDevanter","year":"2011","journal-title":"Med. Devices Evid. Res."},{"key":"B210","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3109\/08982100903103904","article-title":"Development and optimization of solid lipid nanoparticles of amikacin by central composite design","volume":"20","author":"Varshosaz","year":"2010","journal-title":"J. Liposome Res."},{"key":"B211","doi-asserted-by":"publisher","first-page":"136859","DOI":"10.1155\/2013\/136859","article-title":"Biodistribution of amikacin solid lipid nanoparticles after pulmonary delivery","volume":"2013","author":"Varshosaz","year":"2013","journal-title":"Biomed Res. Int."},{"key":"B212","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1477-3155-8-22","article-title":"Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis","volume":"8","author":"Vij","year":"2010","journal-title":"J. Nanobiotechnol."},{"key":"B213","doi-asserted-by":"crossref","first-page":"145","DOI":"10.5772\/61060","article-title":"First insights into non-invasive administration routes for non-viral gene therapy","volume-title":"Gene Therapy \u2013 Principles and Challenges","author":"Villate-Beitia","year":"2015"},{"key":"B214","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1080\/03639045.2017.1298122","article-title":"Gene delivery to the lungs: pulmonary gene therapy for cystic fibrosis","volume":"43","author":"Villate-Beitia","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"B215","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B216","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1002\/jps.23203","article-title":"Interaction of colistin and colistin methanesulfonate with liposomes: colloidal aspects and implications for formulation","volume":"101","author":"Wallace","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"B217","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejpb.2013.08.013","article-title":"Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: a review of the state of the art","volume":"86","author":"Weber","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B218","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00408-011-9360-x","article-title":"Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery","volume":"190","author":"Willis","year":"2012","journal-title":"Lung"},{"key":"B219","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1034\/j.1399-3003.1999.14a38.x","article-title":"Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract","volume":"14","author":"Wise","year":"1999","journal-title":"Eur. Respir. J."},{"key":"B220","first-page":"783","article-title":"Solid lipid nanoparticles (SLN) - A novel carrier for UV blockers","volume":"56","author":"Wissing","year":"2001","journal-title":"Pharmazie"},{"key":"B221","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ijpharm.2008.02.011","article-title":"Inhaled nanoparticles-a current review","volume":"356","author":"Yang","year":"2008","journal-title":"Int. J. Pharm."},{"key":"B222","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/ppul.22813","article-title":"Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides","volume":"48","author":"Young","year":"2013","journal-title":"Pediatr. Pulmonol."},{"key":"B223","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0092-8674(93)80063-K","article-title":"Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis","volume":"75","author":"Zabner","year":"1993","journal-title":"Cell"},{"key":"B224","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1056\/NEJMcibr041584","article-title":"Can curcumin cure cystic fibrosis?","volume":"351","author":"Zeitlin","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B225","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2174\/092986710790416290","article-title":"Development of nanoparticles for antimicrobial drug delivery","volume":"17","author":"Zhang","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"B226","doi-asserted-by":"publisher","first-page":"390","DOI":"10.5246\/jcps.2011.04.049","article-title":"Preparation and characterization of budesonideloaded solid lipid nanoparticles for pulmonary delivery","volume":"20","author":"Zhang","year":"2011","journal-title":"J. Chin. Pharm. Sci."},{"key":"B227","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.micpath.2018.09.010","article-title":"The co-colonization prevalence of Pseudomonas aeruginosa and Aspergillus fumigatus in cystic fibrosis: a systematic review and meta-analysis","volume":"125","author":"Zhao","year":"2018","journal-title":"Microb. Pathog."},{"key":"B228","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1021\/acs.molpharmaceut.6b00036","article-title":"Effect of the route of administration and PEGylation of Poly(amidoamine) dendrimers on their systemic and lung cellular biodistribution","volume":"13","author":"Zhong","year":"2016","journal-title":"Mol. Pharm."}],"container-title":["Frontiers in Bioengineering and Biotechnology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fbioe.2019.00406\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T16:27:54Z","timestamp":1613147274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fbioe.2019.00406\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,17]]},"references-count":228,"alternative-id":["10.3389\/fbioe.2019.00406"],"URL":"https:\/\/doi.org\/10.3389\/fbioe.2019.00406","relation":{},"ISSN":["2296-4185"],"issn-type":[{"value":"2296-4185","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,17]]},"article-number":"406"}}